Scientific database and research platform CiteAb announced on Monday the launch of its CiteAb Explore Platform, comprising the Reagent Search Engine and new Image Search Engine.
Built on over a decade of AI-driven data collection combined with expert human curation, CiteAb's database contains 16 million research tools and their use in 40 million publications, covering antibodies, proteins, models, kits and more. As of 2026, instrument data is also included. This data underpins the Explore Platform, which helps researchers identify fit-for-purpose reagents, faster.
The new Image Search tool is designed to enable researchers to rapidly investigate peer-reviewed scientific images. Developed with input from the scientific community, it provides easy access to 850,000 cropped experimental images -- covering 610,000 proteins, 5,000 diseases, and 160,000 cell lines -- linked directly to publications and the reagents used.
Together, the research tools in CiteAb Explore are intended to help researchers cut time spent navigating fragmented data sources, reduce R&D waste, and achieve more reproducible results.
The CiteAb Explore platform is freely accessible to academics, with a paid subscription model for commercial users.
HUTCHMED doses first patient in global trial of ATTC candidate HMPL-A580
Ensorcell adds new senior leadership team members
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Lynk Pharmaceuticals reveals positive topline results from zemprocitinib Phase III clinical trial
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
ValiRx establishes animal health subsidiary to target veterinary oncology market